Jan Maree Tennent

Jan Maree Tennent FTSE (born 1 January 1960) is an Australian scientist in the biomedical and animal health research sectors, and a member of the Australian Academy of Technology Science and Engineering.[1][2]

Jan Tennent
Born
Melbourne, Victoria, Australia
NationalityAustralian
AwardsBoard Diversity Scholarship
Scientific career
FieldsBiomedical Research and Innovation
InstitutionsBiomedical Research Victoria

Early life and education

Tennent was born in Footscray, Melbourne, Victoria on 1 January 1960. She obtained a Bachelor of Science, in microbiology from the Monash University in Melbourne in 1981. She completed her PhD in 1986 at Monash University. Her PhD thesis was entitled 'Molecular Analysis of Plasmids in Multi-resistant Staphylococci'.

Career

Tennent left Australia in 1986 to do a four-year postdoctoral fellowship with Prof Staffan Normark at Umeå University in Sweden. She researched the genetic mechanism and control of host attachment by uropathogenic Escherichia coli as part of the Normark laboratory's research.[3][4][5][6][7]

Tennet returned to Australia and joined the CSIRO as a Senior Research Scientist. She became the Program Manager of the Vaccines and Immunology Group in 1997. Tennent has researched and given keynote presentations in the field of biotechnology and animal vaccines. [8]

In 2000, Tennent joined the global biotherapy organisation CSL Limited and later became a member of the CSL Animal Health executive team. Tennent joined the international pharmaceutical company Pfizer in 2004. In 2009, Tennent founded ConnectBio Pty Ltd.

In 2011, Tennent was appointed as the Chief Executive Officer of Biomedical Research Victoria, a body that represents Australia's biomedical research. In 2017, Tennent was elected to the AusBiotech Board.

Tennent has published 35 contributions in international peer-reviewed scientific journals (1984-2006) and 8 reviews, theses and book chapters on microbial pathogenesis. She served on research-related committees including the Genetic Manipulation Advisory Committee (now the Office of the Gene Technology Regulator) between 1995 and 2001.

Tennent worked at RMIT University and the University of Melbourne. In 2019 Tennent was elected Fellow of the Australian Academy of Technological Sciences and Engineering (FTSE).[9]

References
  1. "Professor Jan Tennent – Biomedical research leader". ATSE. Retrieved 2019-11-08.
  2. "Prof Jan Tennent FTSE - AusBiotech Ltd". www.ausbiotech.org. Retrieved 2019-11-09.
  3. Marklund BI, Tennent JM, Garcia E, Hamers A, Båga M, Lindberg F, Gaastra W, Normark S. Horizontal gene transfer of the Escherichia coli pap and prs pili operons as a mechanism for the development of tissue-specific adhesive properties. Mol Microbiol. 1992 Aug;6(16):2225-42.
  4. Tennent JM, Lindberg F, Normark S. Integrity of Escherichia coli P pili during biogenesis: properties and role of PapJ. Mol Microbiol. 1990 May;4(5):747-58.
  5. Lindberg F, Tennent JM, Hultgren SJ, Lund B, Normark S. PapD, a periplasmic transport protein in P-pilus biogenesis. J Bacteriol. 1989 Nov;171(11):6052-8.
  6. Hultgren SJ, Lindberg F, Magnusson G, Kihlberg J, Tennent JM, Normark S. The PapG adhesin of uropathogenic Escherichia coli contains separate regions for receptor binding and for the incorporation into the pilus. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4357-61.
  7. Norgren M, Båga M, Tennent JM, Normark S. Nucleotide sequence, regulation and functional analysis of the papC gene required for cell surface localization of Pap pili of uropathogenic Escherichia coli. Mol Microbiol. 1987 Sep;1(2):169-78.
  8. "Jan Tennent - Melbourne Knowledge Week 2019". Jan Tennent - Melbourne Knowledge Week 2019. Retrieved 2019-11-09.
  9. "Professor Jan Tennent – Biomedical research leader". Applied. Retrieved 2019-10-24.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.